Skip to main content
SpringerLink
Log in

Conditioning Regimens

  • Chapter
  • First Online:
Blood and Marrow Transplant Handbook

  • 1172 Accesses

Abstract

When a patient begins the hematopoietic cell transplantation (HCT) process, they are treated with chemotherapy and immunotherapy to suppress their host immune system and treat their underlying malignancy. These therapeutic combinations are collectively known as the conditioning or preparative regimens. Chosen specifically for their activity against the underlying malignancy, these agents also decrease the risk of graft rejection and create physiologic space in the bone marrow and lymph nodes to allow for the engraftment of the new allogeneic or autologous stem cell product. If the HCT is performed for a nonmalignant disorder, the conditioning regime is chosen for its immune-suppressive properties. This chapter lists common regimens, provides guidance on drug dosing in different populations, and provides agent-specific insight into supportive care practices.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Lekakis L, de Padua Silva L, de Lima M. Novel preparative regimens in hematopoietic stem cell transplantation. Curr Pharm Design. 2008;14:1923–35.

    Article  CAS  Google Scholar 

  2. Khouri I. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-Hodgkins lymphoma and chronic lymphocytic leukemia. Hematology. 2006;2006(1):390–7.

    Article  Google Scholar 

  3. Champlin R, Khouri I, Anderlini P, et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation: biology and current indications. Oncology. 2003;17:94–100.

    PubMed  Google Scholar 

  4. Giralt S, Ballen K, Rizzo D, et al. Reduced intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2009;15:367–9.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ponce DM, Sauter C, Devlin S, et al. A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation. Biol Blood Marrow Transplant. 2013;19:799–803.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Sanz J, Picardi A, Hernandex Boluda JC, et al. Impact of graft-versus-host disease prophylaxis on outcomes after myeloablative single-unit umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2013;19:1387–92.

    Article  PubMed  Google Scholar 

  7. Peffault de Latour R, Brunstein CG, Porcher R, et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol Blood Marrow Transplant. 2013;19:1355–60.

    Article  PubMed  Google Scholar 

  8. Castagna L, Bramanti S, Devillier R, et al. Haploidential transplant with post-infusion cyclophosphamide in advanced hodgkin lymphoma. Bone Marrow Transplant. 2017;52(5):1–6.

    Google Scholar 

  9. Solomon SR, Sizemore CA, Sanacore M, et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant. 2015;21:1299–307.

    Article  PubMed  Google Scholar 

  10. Kanda J, Rizzieri DA, Gasparetto C, et al. Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning. Biol Blood Marrow Transplant. 2011;17:867–74.

    Article  PubMed  Google Scholar 

  11. Einhorn LH, Williams SD, Chamnes A, et al. High dose chemotherapy and stem-cell rescue for metastatic germ cell tumors. NEJM. 2007;357:340–8.

    Article  CAS  PubMed  Google Scholar 

  12. Krishnan A, Pasquini MC, Logan B, et al. Autologous haematopoietic stem-cell transplantation followed by allogeneic or autologous haematopoietic stem-cell transplantation for multiple myeloma (BMT CTN 0102): a phase 3 biological assessment trial. NEJM. 2011;12(13):1105–203.

    Google Scholar 

  13. McCarthy PL. Part 1: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem-cell transplantation. J Natl Compr Cancer Netw. 2013;11:35–42.

    Article  CAS  Google Scholar 

  14. Seropian S, Nadkarni R, Jillella AP, et al. Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplantation: outpatient treatment is a viable option. Bone Marrow Transplant. 1999;23(6):599–605.

    Article  CAS  PubMed  Google Scholar 

  15. Jo JC, Kang BW, Jang G, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of toxicity and efficacy. Ann Hematol. 2008;87(1):43–8.

    Article  CAS  PubMed  Google Scholar 

  16. Ringden O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as a conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994;83:2723–30.

    Article  CAS  PubMed  Google Scholar 

  17. Palmer J, McCune J, Perales MA, et al. Personalized busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant. 2016;22:1915–25.

    Article  CAS  PubMed  Google Scholar 

  18. Chunduri S, Dobogai LC, Peace D, et al. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;38:477–82.

    Article  CAS  PubMed  Google Scholar 

  19. Brammer JE, Stentz A, Gajeweski J, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. Biol Blood Marrow Transplant. 2015;21:622–9.

    Article  CAS  Google Scholar 

  20. Kornblit B, Maloney DG, Storb R, et al. Fludarabine/2GY TBI is superior to 2 GY TBI as conditioning for HLA-matched related HCT: a phase III randomized trial. Biol Blood Marrow Transplant. 2013;19:1340–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Al-Ali H, Cross M, Lange T, et al. Low-dose total body irradiation-based regimens as preparative regimens for allogeneic haematopoietic cell transplantation in acute myelogenous leukemia. Curr Opin Oncol. 2009;21:S17–22.

    Article  CAS  PubMed  Google Scholar 

  22. Tosi P, Zamigni E, Ronconi S, et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia. 2000;14:1310–3.

    Article  CAS  PubMed  Google Scholar 

  23. Tricot G, Alberts DS, Johnson C, et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996;2:947–52.

    CAS  PubMed  Google Scholar 

  24. Rossi HA, Becker PS, Emmons RVB, et al. High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkins lymphoma. Bone Marrow Transplant. 2003;31(6):441–6.

    Article  CAS  PubMed  Google Scholar 

  25. Lorch A, Kleinhans A, Kramer A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a randomized prospective trial. J Clin Oncol. 2012;30(8):800–5.

    Article  CAS  PubMed  Google Scholar 

  26. Gutierrez-Delgado F, Holmberg L, Hooper H, et al. Autologous cell transplantation for Hodgkin’s disease: Busulfan, melphalan, and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant. 2003;32(3):279–85.

    Article  CAS  PubMed  Google Scholar 

  27. Linker CA, Owzar K, Powell B, et al. Auto-SCT for AML in second remission: CALGB 9620 study. Bone Marrow Transplant. 2009;44(6):353–9.

    Article  CAS  PubMed  Google Scholar 

  28. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001;28:637–42.

    Article  CAS  PubMed  Google Scholar 

  29. Kasamon YI, Bolanos-Meade J, Prince GT, et al. Outcomes of nonmyeloablative haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33(28):3152–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Atta EH, de Sousa AM, Schirmer MR, Bouzas LF, Nucci M, Abdelhay E. Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia. Biol Blood Marrow Transplant. 2012;18:1876–82.

    Article  CAS  PubMed  Google Scholar 

  31. Ciurea SO, Anderssen BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:523–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Eberly AL, Anderson GD, Bubalo JS, et al. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy. 2008;28(12):1502–10.

    Article  CAS  PubMed  Google Scholar 

  33. McCune JS, Wang T, Bo-Subait K, et al. Association of antiepileptic medications with outcomes after allogeneic hematopoietic cell transplantation with busulfan/cyclophosphamide conditioning. Biol Blood Marrow Transplant. 2019;25(7):1424–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Storb R, Blume KG, O’Donnell MR, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantation: the experience in four centers. Biol Blood Marrow Transplant. 2001;7:39–44.

    Article  CAS  PubMed  Google Scholar 

  35. Anderlini P, Wu J, Gersten I, et al. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol. 2015;2(9):e367–75.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Lichtman SM, Etcubanan E, Budman DR, et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate on patients with renal impairment: a prospective dose adjustment study. Cancer Investig. 2002;20:904–13.

    Article  CAS  Google Scholar 

  37. Beitinjaneh A, McKinney AM, Cao Q, et al. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:300–8.

    Article  CAS  PubMed  Google Scholar 

  38. Xiang E, Ni J, Glotzbecker B, et al. Evaluating the adverse effects of melphalan formulations. J Oncol Pharm Pract. 2019;25(7):1631–7.

    Article  CAS  PubMed  Google Scholar 

  39. Bischoff ME, Blau W, Wagner T, et al. Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on dialysis. Bone Marrow Transplant. 1998;22:591–3.

    Article  CAS  PubMed  Google Scholar 

  40. Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transplant. 2014;20:600–16.

    Article  CAS  PubMed  Google Scholar 

  41. Carlson K. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant. 2005;35:985–90.

    Article  CAS  PubMed  Google Scholar 

  42. Dagher R, Kreissman S, Robertson KA, et al. High dose chemotherapy with autologous peripheral blood progenitor cell transplantation in an anephric child with recurrent wilms tumor. J Ped Hematol Oncol. 1998;20:357–60.

    Article  CAS  Google Scholar 

  43. Haubitz M, Bohnenstengel F, Brunkhorst R, et al. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int. 2002;61:1495–501.

    Article  CAS  PubMed  Google Scholar 

  44. Lee CK, Zangari M, Barlogie B, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2002;33(8):823–8.

    Article  CAS  Google Scholar 

  45. Nath CE, Shaw PJ, Montgomery K, et al. Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. Br J Clin Pharm. 2014;59(3):314–24.

    Article  CAS  Google Scholar 

  46. Perry JJ, Fleming RA, Rocco MV, et al. Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation for acute leukemia and end-stage renal disease. Bone Marrow Transplant. 1999;23:839–42.

    Article  CAS  PubMed  Google Scholar 

  47. Bodge MN, Culos KA, Haider SN, et al. Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic hepatic impairment: analysis of the literature and recommendations. Biol Blood Marrow Transplant. 2014;20:89–96.

    Article  Google Scholar 

  48. Grazzuitti ML, Dong L, Miceli MH, et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant. 2006;38:501–6.

    Article  CAS  Google Scholar 

  49. Shea TC, Flaherty M, Elias A, et al. A Phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol. 1989;7:651–61.

    Article  CAS  PubMed  Google Scholar 

  50. Termuhlen AM, Grovas A, Klopfenstein K, et al. Autologous hematopoietic stem cell transplant with melphalan and thiotepa is safe and feasible in pediatric patients with low normalized glomerular filtration rate. Pediatr Transplant. 2006;10:830–4.

    Article  CAS  PubMed  Google Scholar 

  51. Eklund JW, Trifilio S, Mulcahy MF, et al. Chemotherapy dosing in the setting of liver dysfunction. Oncology. 2005;19(8):1057–63.

    PubMed  Google Scholar 

  52. Superfin D, Ianucci AA, Davies AM. Commentary: oncologic drugs in patients with organ dysfunction: a summary. Oncologist. 2007;12(9):1070–83.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacy Services, Oregon Health & Science University, Portland, OR, USA

    Joseph Bubalo

Authors
  1. Joseph Bubalo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph Bubalo .

Editor information

Editors and Affiliations

  1. Center for Hematologic Malignancies Adult Blood and Marrow Transplant & Cell Therapy Program, Knight Cancer Institute Oregon Health & Science University, Portland, OR, USA

    Richard T. Maziarz

  2. Center for Hematologic Malignancies Adult Blood and Marrow Transplant & Cell Therapy Program, Knight Cancer Institute Oregon Health & Science University, Portland, OR, USA

    Susan Schubach Slater

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bubalo, J. (2021). Conditioning Regimens. In: Maziarz, R.T., Slater, S.S. (eds) Blood and Marrow Transplant Handbook. Springer, Cham. https://doi.org/10.1007/978-3-030-53626-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53626-8_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53625-1

  • Online ISBN: 978-3-030-53626-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation